EMPA-REG OUTCOME: cardiovascular outcome trials in diabetes come of age

Abstract

Without question, the highlight of the 2015 European Association for the Study of Diabetes conference in Stockholm was the presentation – to a capacity audience – of the results of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG) OUTCOME trial. This was a highly fitting event for the Association, which celebrated its 50th anniversary last year, the aims of which are innovation and clinical relevance. Moreover, the study is an exceptional example of the clinical relevance of metabolic and cardiovascular interactions in patients with diabetes.